{"id":"NCT05087030","sponsor":"Gedeon Richter Plc.","briefTitle":"Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis","officialTitle":"A Randomised, Double Blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women With Postmenopausal Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-21","primaryCompletion":"2023-10-02","completion":"2023-11-15","firstPosted":"2021-10-21","resultsPosted":"2024-10-24","lastUpdate":"2024-10-24"},"enrollment":473,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"RGB-14-P","otherNames":[]},{"type":"DRUG","name":"Prolia®","otherNames":[]}],"arms":[{"label":"RGB-14-P (Main period)","type":"EXPERIMENTAL"},{"label":"Prolia® (Main period)","type":"ACTIVE_COMPARATOR"},{"label":"RGB-14-P (Transition period)","type":"EXPERIMENTAL"},{"label":"Prolia® (Transition period)","type":"ACTIVE_COMPARATOR"},{"label":"RGB-14-P (Continued till transition period)","type":"EXPERIMENTAL"}],"summary":"This study will be conducted to assess the efficacy, pharmacodynamic (PD), safety, tolerability, and immunogenicity of RGB -14- P compared to US-licensed Prolia® in participants with postmenopausal osteoporosis, in a comparative manner.","primaryOutcome":{"measure":"Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD)","timeFrame":"Week 52","effectByArm":[{"arm":"Main Period: RGB-14-P","deltaMin":5.68,"sd":3.535},{"arm":"Main Period: Prolia®","deltaMin":5.19,"sd":4.118}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"60 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":21},"locations":{"siteCount":59,"countries":["United States","Bulgaria","Czechia","Hungary","Italy","Poland","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":242},"commonTop":["Nasopharyngitis","Hypocalcaemia","COVID-19","Upper respiratory tract infection","Urinary tract infection"]}}